Latest Commercialisation News

NH3 Clean Energy has secured Federal Major Project Status for its WAH2 clean ammonia project, backed by a Linde Engineering FEED agreement and a robust public benefits forecast supporting government-backed financing.

Finder Energy has secured key regulatory approval for its KTJ Project in Timor-Leste and raised $27 million to advance development, positioning for a Final Investment Decision in Q3 2026.

Godolphin Resources has unveiled a significant polymetallic sulphide discovery at Cousin Jack within its Lewis Ponds Project, alongside progressing an IPO to spin out its Narraburra Rare Earths asset into Matrix Critical Minerals.

Anson Resources has dramatically expanded its Green River Lithium Project resource and confirmed robust project economics, while sealing a key agreement with POSCO for a demonstration plant funded by the Korean industrial giant.

Janus Electric navigated a transitional Q4 FY26 by settling legacy debts, raising $12 million, and growing its North American order book to 112 truck conversions, positioning itself for commercial scale-up.

Synertec has locked in a $4 million contract to upgrade AGL’s national SCADA system, reinforcing its foothold in critical infrastructure technology as it forecasts up to 50% revenue growth in FY27.

dorsaVi has confirmed its RRAM memory and neuromorphic IP operate synergistically, projecting up to 10x performance gains for robotics and exoskeletons. The company also finalized its first integrated RRAM-CMOS validation chip design, advancing towards tape-out and commercialisation.

NOVONIX has hit a critical milestone by delivering a synthetic graphite anode sample to Panasonic, supporting a planned production start in late 2027. The company secured A$21.66 million in fresh capital to fund production readiness, while navigating an evolving US trade and policy landscape aimed at boosting domestic battery materials.

Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.

HITIQ Limited has fortified its financial position through a $1.4 million placement and secured milestone-based Victorian Government funding, accelerating its manufacturing expansion and commercial growth in concussion management technology.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.